Preliminary data from the world’s first national meningitis B immunisation programme with Bexsero1, launched one year ago in the UK, shows the estimated effectiveness of the vaccine at 83 percent against any meningitis B strain and 94 percent.
Dr. Reddy’s Laboratories Ltd announced that it has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin® SR (bupropion HCl) Sustained-Release Tablets in the United States market approved by the U.S. FDA.
TaiGen Biotechnology Company, Limited announced that they have signed an exclusive licensing agreement with Productos Científicos S.A. de C.V. ("PC"), a leading Mexican pharmaceutical company, to develop and commercialize Taigexyn® (nemonoxacin) in Latin America.
AstraZeneca announced that it has completed the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US.
The FDA has again raised issues at an Alexion plant that three years ago was issued a warning letter. The facility is where Alexion manufactures what has been deemed the world’s most expensive drug, Soliris.